Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 176

Results For "Oval"

2716 News Found

Heuron gets FDA green light for stroke triage and notification solution
News | May 25, 2024

Heuron gets FDA green light for stroke triage and notification solution

This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea


Swixx Biopharma acquires Biopas to expand in Latin America
News | May 24, 2024

Swixx Biopharma acquires Biopas to expand in Latin America

The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies


Taro shareholders approve merger with Sun Pharma
News | May 24, 2024

Taro shareholders approve merger with Sun Pharma

The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world


Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19
Clinical Trials | May 20, 2024

Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19

SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients


Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA
Clinical Trials | May 20, 2024

Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA

95.7% of patients responded to Breyanzi in the TRANSCEND FL trial


Biocon posts Q4 FY24 PAT at Rs. 135 Cr
News | May 17, 2024

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%


Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause
Clinical Trials | May 17, 2024

Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause

Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms


Moderna update on investigational RSV vaccine
Drug Approval | May 14, 2024

Moderna update on investigational RSV vaccine

U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024


AstraZeneca completes equity investment agreement with Cellectis
News | May 08, 2024

AstraZeneca completes equity investment agreement with Cellectis

Cellectis is also eligible to receive an investigational new drug (IND) option fee and development